



## PRESS RELEASE

### SUCCESSFUL CONCLUSION TO THE INCREASE IN CAPITAL, ALL OPTION RIGHTS SOLD

Capua, 14 April 2015 – **Pierrel S.p.A.** (“**Pierrel**” or the “**Company**”) discloses that today saw the successful conclusion of the rights issue (the “**Offer**”) to shareholders of a maximum of **4,916,279** newly issued ordinary shares of the Company, with no nominal value (the “**Shares**”).

During the period from **23 March 2015** and **10 April 2015** (the “**Rights Period**”) **39,849,410** option rights were exercised and valid for the subscription to **3,984,941** Shares, being **81.06** % of the Offer, with a total value of € **2,789,458.70**.

Pursuant to Article 2441, third paragraph of the civil code, Pierrel then offered on the Stock Exchange (the “**Stock Exchange Offer**”) 9,313,380 option rights that were not exercised during the rights period (the “**Unexercised Rights**”) valid for the subscription to 931,338 Shares, with a total value of € 651,936.60.

The unexercised rights were fully sold in the first trading session of the Stock Exchange Offer held today.

**The Offer** therefore concluded with the sale of the entire **39,849,410** option rights that, if fully exercised, would determine the subscription of **all the 4,916,279** Shares offered, for a total value of € **3,441,395.30**.

The exercise of the Unexercised Rights acquired within the scope of the Stock Exchange Offer and, consequently, the subscription to the corresponding Shares must be made, otherwise they will lapse, before and not after the third working day from the communication of the early closing and thus before and not after 17 April 2015

It is noted, lastly, that the Unexercised Rights will be made available to the acquirers by way of the authorised intermediaries that are members of Monte Titoli S.p.A. and such Unexercised Rights may be used for the subscription to Shares at a price of € 0.70 per Share, on the basis of 1 Share for every 10 Unexercised Rights exercised.

\* \* \*

*This communication does not constitute an offer or an invitation to subscribe for or purchase any securities. The securities referred to herein have not been registered and will not be registered in the United States under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or in Australia, Canada or Japan or any other jurisdiction where such an offer or solicitation would require the approval of local authorities or otherwise be unlawful. The securities referred to herein may not be offered or sold, directly or indirectly, in the United States or to U.S. persons unless such securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. There will be no public offer of securities in the United States, Australia, Canada or Japan. Copies of this announcement are not being made and may not be distributed or sent into the United States, Canada, Australia or Japan.*

\*\*\*

**Pierrel S.p.A.** is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).



Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System ("DRR2.0") and Integrated Clinical Development Services ("ICDS") for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 23 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical use. The database can be accessed by molecule or by illness. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe.

The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

**For further information:**

**Pierrel S.p.A.**

*Investor Relations*

Dr Raffaele Petrone

*e-mail:*

[investor.relations@pierrelgroup.com](mailto:investor.relations@pierrelgroup.com)

tel. +39 0823 626 111

fax +39 0823 626 228

**Global Consult S.r.l.**

*Media Relations*

Rossana Del Forno

*e-mail:*

[areacomunicazione@globalconsultsrl.com](mailto:areacomunicazione@globalconsultsrl.com)

tel. +39 333 6178665